Composition comprising thrombin-treated stem cell-derived exosome for treating skin wound

Patent metadata

Field	Value
Publication number	US-12239695-B2
Application number	US-201716314725-A
Country	US
Kind code	B2
Filing date	Jun 27, 2017
Priority date	Jul 1, 2016
Publication date	Mar 4, 2025
Grant date	Mar 4, 2025

Abstract

The present disclosure relates to a pharmaceutical composition comprising an exosome derived from a thrombin-treated stem cell as an effective ingredient for preventing or treating a skin wound, a pharmaceutical formulation containing the same, and a production method thereof. Being a cell-free agent, an exosome-based therapeutic agent of the present disclosure has a low risk of carcinogenesis and no problems of graft rejection as well as being little liable to occur microvascular obstruction. The agent, which is not a cell, but a material isolated from a cell, can be subjected to medication development into an off-the-shelf product which allows for the reduction of production cost. The agent has the advantage of exhibiting outstanding angiogenesis and skin wound treatment effects even at a low concentration of exosomes thanks to the thrombin treatment effect.

First claim

What is claimed is:

1. A method of treating skin wound, comprising:
administering to a subject in need thereof an effective amount of exosomes derived from thrombin-treated stem cells.

2. A method according to claim 1 , wherein the stem cells are selected from the group consisting of mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells and multipotent stem cells.

3. A method according to claim 2 , wherein the mesenchymal stem cells are derived from umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, amniotic membrane or placenta.

4. A method according to claim 1 , wherein the treatment of skin wounds is caused by angiogenesis due to the promotion of the growth of vascular endothelial cells.

5. A method according to claim 1 , further comprising:
administering to a subject in need thereof an effective amount of a supplementary ingredient selected from group consisting of a culture medium, a cytokine, a growth factor and a gene.

6. A method according to claim 1 , wherein the exosomes are increased in the expression of a growth factor, an immunoregulatory factor, an antioxidation factor or an angiogenesis factor.

7. A method according to claim 6 , wherein the growth factor is a brain-derived neurotropic factor (BDNF), a fibroblast growth factor (FGF), a hepatocyte growth factor (HGF), a nerve growth factor (NGF), or a vascular endothelial growth factor (VEGF).

Assignees

• Samsung Life Public Welfare Foundation

Inventors

• Chang Yun Sil
• Park Won Soon
• Sung Dong Kyung
• Ahn So Yoon

Classifications

• A61K35/28 Primary

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• A61K9/70

  Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)} · CPC title

• A61K9/12 Primary

  Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)} · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61K38/4833 Primary

  Thrombin (3.4.21.5) · CPC title